Roundup Settlement Before Christmas? Bayer CEO Says $7.25 Billion Approval 'Could Be Any Week Now'

Roundup settlement before Christmas: what Bayer said on Nov. 3

Bayer expects the $7.25 billion Roundup class settlement to receive final court approval before Christmas, CEO Bill Anderson said on Tuesday, Nov. 3, 2026, telling reporters that a ruling "could be any week now." The forecast matters because the deal, pending before Judge Timothy Boyer in the Circuit Court of the City of St. Louis since a Sept. 14 fairness hearing, would resolve most of the roughly 65,000 outstanding non-Hodgkin lymphoma claims and start the claims process for a nationwide class, although objector appeals could still push back the date money actually moves.

The comment came on the day Bayer reported third-quarter results, and it was the first time the company has put a calendar marker on a decision that has slipped repeatedly since February. It is a prediction by a litigant, not a signal from the bench: Judge Boyer has issued no order on final approval, and nothing in the public record indicates when he will. But a Roundup settlement before Christmas is now the expectation Bayer has set for investors, and it frames how claimants, opt-out counsel, lienholders and the remaining Multidistrict Litigation (MDL) docket should plan the next eight weeks.

Anderson made two further points that practitioners should register. First, he said there would be a much smaller number of individual cases left once the settlement takes effect. Second, he told analysts on the earnings call that many people who opted out of the class, and lawyers representing opt-outs, are now trying to get back in, and that he expects the opt-out count to fall through an administrative process after a final ruling. That second point is the more consequential one for the plaintiffs' bar, and it is addressed in detail below.

When will the Roundup settlement be approved?

No court has set a date. The only forecast on the record is Bayer's: approval before Christmas 2026, possibly "any week now." The decision belongs to Judge Boyer alone, under Missouri Supreme Court Rule 52.08, the state's class action rule, which mirrors Rule 23 in requiring the court to find a settlement fair, reasonable and adequate before it binds absent class members.

The procedural path to this point explains why Bayer is confident and why it has been wrong before:

Date	Event
Feb. 17, 2026	Monsanto announces the proposed nationwide class settlement in King v. Monsanto Co.; futures subclass defined by U.S. exposure before this date
March 4, 2026	Judge Boyer grants preliminary approval and orders class notice
June 4, 2026	Opt-out and objection deadline
June 25, 2026	U.S. Supreme Court decides Monsanto Co. v. Durnell, 7-2, holding FIFRA preempts label-based failure-to-warn claims
June 30, 2026	Order vacating the original July 9 fairness hearing and resetting it to Aug. 19
Aug. 2026	Parties seek a further continuance after a wave of opt-out revocation requests
Sept. 4, 2026	Special master report reportedly recommends rejecting most objections
Sept. 14, 2026	Final fairness hearing; Judge Boyer reserves decision and asks for proposed orders
Oct. 29, 2026	Monsanto wins a unanimous defense verdict in Aretino v. Monsanto Co. (St. Louis County)
Nov. 3, 2026	Anderson says Bayer expects the settlement "before Christmas"

Does Bayer's forecast mean the judge has signaled a ruling?

Not on the public record. Nothing reported indicates that Judge Boyer has told the parties when he will rule or which way. Defendants routinely give investors timing guidance based on their own reading of a docket, and the calendar for this deal has already slipped twice, from a July 9 hearing to Aug. 19 and then to Sept. 14. What the forecast does show is that Bayer sees no remaining procedural obstacle between the closed record and a decision: the proposed orders have been filed, the special master has reported, and the remand fight over federal jurisdiction is over. A Roundup settlement before Christmas is therefore a plausible reading of the docket, not a disclosed fact about chambers.

Seven weeks have now passed since the fairness hearing. That is not unusual for a settlement of this size and novelty, particularly one that asks a state trial court to certify a Settlement Class including people who have not yet been diagnosed. A long, reasoned opinion is the defense against reversal on appeal, and both sides have every incentive to want Judge Boyer to take the time to write one.

What did Bayer's CEO say about the Roundup settlement?

Reuters reported that Anderson said the company expects the settlement "to come before Christmas," and that approval "could be any week now," speaking on a press call after the results were released. He also said that, after the settlement, there would be a much smaller number of individual cases remaining. Reuters noted that the proposed agreement is under review by a Missouri state court judge in St. Louis.

On the analyst call the same day, according to the Investing.com transcript summary, Anderson said the opt-out deadline had passed in early June and that quite a few opt-outs, along with plaintiffs' counsel representing them, are now seeking to rejoin. He suggested that after a final ruling some of those claimants would come back in through an administrative process and that the number of opt-outs should decline over time.

The financial backdrop gives the comment context. Bayer raised its 2026 adjusted EBITDA guidance to 9.8 billion to 10.3 billion euros, from 9.6 billion to 10.1 billion euros, on stronger pharmaceutical results, and cut its expected year-end net financial debt by 1 billion euros to between 28 billion and 29 billion euros. When it announced the class deal in February, Bayer said it expected litigation-related cash payments of about 5 billion euros in 2026, covering the largest annual payments into the class settlement, glyphosate settlements outside the class, and PCB settlements, and that it had signed an $8 billion bank loan facility to fund them. At that time it also raised its litigation provisions to 11.8 billion euros from 7.8 billion euros and guided to negative free cash flow for 2026. Bayer did not publicly revise those litigation numbers on Nov. 3, as far as the reporting reviewed for this article shows.

Can I rejoin the Roundup settlement after opting out?

Possibly, but not as of right. The June 4, 2026 opt-out deadline has passed, and a person who validly excluded themselves is, on paper, outside the class. Bayer's CEO said on Nov. 3 that many opt-outs are trying to get back in and that he expects some to rejoin through an administrative process after a final ruling. Whether, and on what terms, a given opt-out can revoke depends on what Judge Boyer's final order permits and on Monsanto's consent.

The rush back toward the class has a clear cause: Monsanto Co. v. Durnell. On June 25, 2026, the Supreme Court held 7-2 that the Federal Insecticide, Fungicide, and Rodenticide Act preempts state-law failure-to-warn claims that would require a cancer warning beyond what the EPA-approved label contains. The decision gutted the theory that produced most of the large Roundup verdicts, and with it much of the leverage that justified opting out. Reporting before the fairness hearing described firms whose clients had planned to opt out reconsidering after Durnell; one firm said 800 to 900 of its clients fell into that category.

The trial record since then has reinforced the point. On Oct. 29, 2026, a St. Louis County jury returned a unanimous defense verdict in Aretino v. Monsanto Co., the first Roundup trial since Durnell, rejecting the Design Defect, negligence and fraud theories of three Florida plaintiffs who were not participating in the class deal. On Oct. 13, the Supreme Court had already vacated and remanded the $28 million Dennis verdict from California in light of Durnell. For an opt-out client, the calculation has shifted from "trial value versus grid value" to "uncertain trial value, years away, versus a guaranteed grid award."

Two structural features make revocation more than a formality:

• The walk-away right. Bayer has said it holds a right to terminate the settlement, without paying claims, if opt-outs are excessive. It has declined to disclose the threshold but has said participation must be "very close to 100%" to deliver closure. Every revocation moves Bayer further from that line, which is why the company has an interest in an orderly re-entry process.
• Monsanto's leverage over terms. Because re-entry after the deadline is a concession, the defendant can, in principle, condition it. Counsel should not assume a returning opt-out receives exactly the award it would have received by staying in, or the same claim timing.

How does the Durnell decision affect Roundup claims outside the settlement?

Durnell removed the label-based Failure to Warn theory but left other theories alive, at least for now. Design defect, negligence not tied to the label, and fraud-type claims survived in some courts and failed at trial in Aretino. In the federal MDL, Judge Vince Chhabria of the Northern District of California, who presides over MDL 2741, invited amicus briefing in October on whether Durnell also preempts negligence, design defect and warranty claims under the laws of Florida, Ohio, North Carolina, Mississippi, Georgia and Arizona. A broad ruling would narrow the opt-out path further; a narrow one would preserve a residual trial docket.

The interplay with the class matters for timing. Monsanto has every reason to keep defending opt-out cases hard while the approval decision is pending, because each defense verdict lowers the reservation price of the remaining holdouts. Plaintiffs' firms with mixed inventories, some clients in the class and some out, face the reverse pressure.

How much will each person get from the Roundup settlement?

The settlement does not pay a uniform amount. According to the agreement as summarized by the parties and the settlement website, it pays up to $7.25 billion in declining, capped annual installments over as long as 21 years, secured by a $1 billion security fund. Individual awards run from roughly $10,000 to $165,000 across nine tiers, keyed to the setting of exposure (occupational or residential), age at diagnosis, and disease severity. The class is split into two subclasses:

Subclass	Who is in it	When they can claim
Current claimants	People exposed to Roundup in the U.S. who have already been diagnosed with non-Hodgkin lymphoma	Registration opens after final approval; claims proceed once the settlement is effective
Future claimants	People exposed in the U.S. before Feb. 17, 2026 who have not been diagnosed	Only upon a later diagnosis; rights are restored if no diagnosis arrives by the sixteenth annual payment date

The grid is the reason the settlement is attractive to some and objectionable to others. A $10,000 floor is modest compared with Roundup verdicts before Durnell, and the top tier is well below what plaintiffs asked juries for in individual trials. But the grid pays without a causation fight, and the funding schedule is backed by a balance sheet that has, as of Nov. 3, a raised outlook and an $8 billion credit line earmarked in part for exactly these payments. Class counsel's $675 million fee request, about 9.3% of the maximum fund and payable from inside it, will also be decided by Judge Boyer; any reduction would leave more money in the grid but does not change the tier values directly.

Individual net recoveries will be lower than the gross tier figures for most claimants. Private counsel fees under a Contingency Fee agreement, case expenses, any Common Benefit Fund assessment, and Medicare, Medicaid and private insurer reimbursement claims asserted as a Medical Lien all come off the top. Roughly a dozen health plans objected to the settlement, in part over how their lien rights are treated, and that issue will shape net payouts for anyone with substantial treatment costs.

When will Roundup settlement payments start?

Not at final approval. Under the settlement's mechanics as summarized by settlement trackers, registration for current claimants runs for 180 days after final approval, and the claim deadline falls 180 days after any appeals are resolved. Payments then flow through the Claims Administrator in capped annual installments. A Roundup settlement before Christmas therefore starts the registration window, not the check-writing.

The real variable is appeal. More than 100 class members and about a dozen health plans objected before the fairness hearing, attacking class notice, the opt-out process, the court's jurisdiction over non-Missouri residents, the release of Punitive Damages, and the fee request. Any objector whose objection is overruled can appeal a final judgment to the Missouri Court of Appeals, Eastern District, and from there seek transfer to the Supreme Court of Missouri. The settlement does not become effective until those appeals are exhausted.

History suggests the delay can be material. The earlier, unrelated $45 million Roundup advertising class settlement, Gilmore v. Monsanto Co., won final approval in March 2023 but did not begin distributing payments until October 2024, after appeals were resolved. That was a much smaller and less contested deal.

The federal dimension adds risk. Objectors tried to remove the case to federal court, and a Missouri federal judge sent it back to state court. Judge Chhabria, outside the case, has publicly questioned whether a Missouri state court can bind Roundup users who live elsewhere and people who have not yet developed cancer. Those are the arguments an appellate court will be asked to take up, and they echo the limits the U.S. Supreme Court placed on settlement-only classes in Amchem Products, Inc. v. Windsor (1997) and Ortiz v. Fibreboard Corp. (1999), both of which turned on the treatment of exposure-only future claimants.

What happens if the judge rejects the Roundup settlement?

If Judge Boyer denies final approval, the class settlement fails and the parties return to litigation, or to renegotiation. Claims would revert to the individual dockets in state courts and the federal MDL, where Durnell now constrains the most common theory. Bayer has said the class deal is its only settlement vehicle for remaining claims, and it was widely reported before February to be weighing a Monsanto bankruptcy filing if litigation could not be contained. A denial is not the expected outcome given the special master's reported recommendation and the absence of any reported signal from the bench, but it cannot be excluded.

A partial outcome is also possible. The court could approve the current-claimant subclass while declining to certify the futures subclass, or condition approval on changes to notice, fees or lien treatment. Bayer's walk-away right would then become relevant again.

What Judge Boyer still has to decide

The approval order will have to answer five clusters of objections, each of which doubles as a preview of the appeal that is likely to follow whichever way he rules.

Notice. Objectors argued that notice to a nationwide class, much of it composed of people who do not know they were exposed and have no diagnosis, could not satisfy due process. Class Notice for an exposure-only population is the hardest notice problem in aggregate litigation, because the people who most need to read it have the least reason to.

Opt-out mechanics. The challenge here concerns how exclusions were collected and counted, and whether mass opt-outs submitted by law firms on behalf of inventories were valid. The post-Durnell reversal adds a new question the original objections did not anticipate: if the court allows revocations, on what showing, and by what date?

Jurisdiction over non-Missouri residents. Phillips Petroleum Co. v. Shutts (1985) allows a state court to bind absent class members who lack contacts with the forum if they receive notice, an opportunity to opt out, and adequate representation. Objectors contend the futures subclass cannot meaningfully exercise an opt-out right it does not know it has. This is the argument Judge Chhabria flagged from the federal bench, and it is the one most likely to draw appellate attention.

Release of punitive damages. The settlement releases Punitive Damages claims, a significant concession for a defendant that has faced nine-figure punitive awards in prior Roundup trials. Objectors argued the compensatory grid does not price that release. Monsanto's answer, sharpened by Durnell, is that punitive exposure has fallen with the failure-to-warn theory that generated it.

Fees and adequacy. Class counsel's $675 million request and the Adequacy of Representation question for futures claimants travel together. Under Amchem and Ortiz, a single set of counsel representing currently injured and exposure-only claimants needs structural protections, such as separate subclass counsel, to show that neither group was traded off against the other.

The special master's Sept. 4 report reportedly recommended rejecting most of these challenges. Judge Boyer is not bound by it, but a final order that adopts its reasoning would give appellate courts a fuller record to review. Appellate courts generally review settlement approval for abuse of discretion, a deferential standard, which is one reason a detailed written order is more valuable to the parties than a fast one.

Opt-out class versus opt-in deal: why the walk-away clause matters

The Roundup structure differs from the other mega-settlement now in play in mass torts, and the difference explains why Bayer is talking about opt-outs at all.

Feature	Roundup class (King v. Monsanto Co.)	J&J ovarian talc proposal (MDL 2738)
Vehicle	Rule 52.08 Settlement Class in Missouri state court	Inventory deal requiring firms to sign on
Default for claimants	In unless they opted out by June 4, 2026	Out unless their firm opts in
Headline amount	Up to $7.25 billion over up to 21 years	$5.5 billion
Participation condition	Undisclosed opt-out walk-away; "very close to 100%" target	At least 95% of roughly 76,000 remaining claims
Reported participation	Opt-outs falling as some seek re-entry, per Bayer, Nov. 3	About 87.5% as reported in October 2026
Future claimants	Futures subclass included	Not included
Court role	Fairness finding binds absent members	No class fairness finding

In an opt-out class, inertia works for the defendant: every class member who does nothing is bound. In an opt-in inventory deal, inertia works against it: every claimant who does nothing remains a litigant. That is why J&J's public metric is how many firms have signed, while Bayer's is how many people have left. After Durnell, the second number has moved in Bayer's favor, and Anderson's comments signal that the company intends to use the post-approval period to shrink it further rather than to invoke the walk-away right.

The table also shows the trade-off that makes the Roundup approval more vulnerable on appeal. A fairness finding that binds absent members, including people who are not yet sick, is a more powerful instrument than a negotiated inventory deal, and it receives more scrutiny for that reason.

Roundup settlement before Christmas: what to watch next

• The approval order itself. Its length and its treatment of the futures subclass and the Shutts argument will indicate how exposed it is on appeal.
• Any revocation procedure. Whether the order or a later administrative protocol lets opt-outs return, and by what deadline, is the practical question for the plaintiffs' firms holding opt-out inventories.
• The fee ruling. Whether Judge Boyer awards the full $675 million or trims it.
• Notices of appeal. Objectors who were overruled will have a short window to appeal; the number and identity of appellants will indicate whether the effective date is months or years away.
• MDL 2741. Judge Chhabria's ruling on whether Durnell reaches negligence and design defect claims under the six states' laws he identified will set the value of the opt-out cases that remain.
• Bayer's next filings. Any change in litigation provisions or 2026 cash-payment guidance would signal how the company is reading the approval timing.

What it means for claimants, opt-out counsel and lienholders

For class members with a diagnosis. A ruling before Christmas would open registration. Claimants should expect the formal process, gathering exposure proof, diagnosis records and age-at-diagnosis evidence for tier placement, to start in early 2027, with payment timing driven by appeals rather than by the approval date.

For opt-out counsel. The question is now how, not whether, to re-enter. Firms holding opt-out inventories should expect Monsanto to prefer a structured, court-supervised revocation process after the final order, and should anticipate that late re-entry may carry different timing or terms. Clients with design defect or non-label negligence theories in states where Judge Chhabria's amicus process may produce a favorable ruling are the strongest candidates to stay out; most others face a weaker position than they did in May.

For PI firms and funders. A Roundup settlement before Christmas would end the leverage window for litigation-funded opt-out inventories. Third-Party Litigation Funding priced on pre-Durnell verdict values will be marked down, and the 21-year payment tail will matter to any firm whose economics depend on the timing of fee receipts.

For health plans and lienholders. The treatment of reimbursement rights is one of the issues objectors raised. Plans should be ready to assert and resolve liens through the claims process once the court rules, and to evaluate whether an appeal on lien terms is worth delaying a recovery they can otherwise collect.

For Bayer's other litigation. The opt-out dynamic, a Supreme Court preemption win followed by a run back toward a settlement class, is a template the defense bar will study for other pesticide and product dockets. It also strengthens the argument that a well-funded class grid, paired with a favorable federal ruling, can achieve near-total participation without resort to a Texas Two-Step or Section 524(g) Trust.

Frequently asked questions

When will the Roundup settlement be approved?

Bayer expects final approval before Christmas 2026, and its CEO said on Nov. 3 that it "could be any week now," but Judge Timothy Boyer of the Circuit Court of the City of St. Louis has set no date and has not ruled since the Sept. 14 fairness hearing.

Is the $7.25 billion Roundup settlement final?

No. As of Nov. 3, 2026, the settlement has preliminary approval only (granted March 4, 2026). It becomes effective only after final approval and the resolution of any appeals.

Can I still join the Roundup settlement?

Class members who did not opt out are already in. People who opted out by the June 4, 2026 deadline cannot rejoin automatically; Bayer says it expects some to return through an administrative process after a final ruling, on terms the court and Monsanto will control.

How much is the Roundup settlement payout per person?

Individual awards range from roughly $10,000 to $165,000 across nine tiers based on exposure type, age at diagnosis and disease severity, before attorney fees, expenses and medical lien reimbursement.

When will Roundup settlement checks be sent?

Not immediately after approval. Settlement summaries describe a 180-day registration window after final approval and a claim deadline 180 days after appeals end, so payments are unlikely before 2027 and could take longer if objectors appeal.

Does the Aretino verdict affect the settlement?

Not directly. The Oct. 29 defense verdict in Aretino v. Monsanto Co. involved three plaintiffs outside the class and sets no binding precedent, but it strengthens Monsanto's position against opt-outs and helps explain why some now want back in.